WO2007111020A1 - 局所脳血流診断用放射性医薬品製造用組成物 - Google Patents
局所脳血流診断用放射性医薬品製造用組成物 Download PDFInfo
- Publication number
- WO2007111020A1 WO2007111020A1 PCT/JP2007/000283 JP2007000283W WO2007111020A1 WO 2007111020 A1 WO2007111020 A1 WO 2007111020A1 JP 2007000283 W JP2007000283 W JP 2007000283W WO 2007111020 A1 WO2007111020 A1 WO 2007111020A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salt
- composition
- ecd
- labeling
- sodium
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title description 12
- 230000003727 cerebral blood flow Effects 0.000 title description 11
- 238000003745 diagnosis Methods 0.000 title description 5
- 230000002285 radioactive effect Effects 0.000 title description 2
- 150000003839 salts Chemical class 0.000 claims abstract description 69
- 239000000126 substance Substances 0.000 claims abstract description 18
- 230000002378 acidificating effect Effects 0.000 claims abstract description 17
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- BWUXDKMMCZJFAB-UHFFFAOYSA-N oxotechnetium Chemical compound [Tc]=O BWUXDKMMCZJFAB-UHFFFAOYSA-N 0.000 claims abstract description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 51
- 235000010323 ascorbic acid Nutrition 0.000 claims description 25
- 229960005070 ascorbic acid Drugs 0.000 claims description 25
- 239000011668 ascorbic acid Substances 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 13
- 150000002148 esters Chemical class 0.000 claims description 13
- -1 1,2-ethylene Chemical group 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 7
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 6
- 239000004158 L-cystine Substances 0.000 claims description 5
- 229960003067 cystine Drugs 0.000 claims description 5
- 239000005977 Ethylene Substances 0.000 claims description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 229960005219 gentisic acid Drugs 0.000 claims description 3
- 239000012279 sodium borohydride Substances 0.000 claims description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims 1
- 150000001340 alkali metals Chemical group 0.000 claims 1
- 150000004764 thiosulfuric acid derivatives Chemical class 0.000 claims 1
- 238000002372 labelling Methods 0.000 abstract description 51
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 239000004201 L-cysteine Substances 0.000 abstract 1
- HKASNZKRIQURIX-BZDVOYDHSA-N ethyl (2r)-2-[2-[[(2r)-1-ethoxy-1-oxo-3-sulfanylpropan-2-yl]amino]ethylamino]-3-sulfanylpropanoate;dihydrochloride Chemical compound Cl.Cl.CCOC(=O)[C@H](CS)NCCN[C@@H](CS)C(=O)OCC HKASNZKRIQURIX-BZDVOYDHSA-N 0.000 description 46
- 239000000243 solution Substances 0.000 description 40
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 15
- 210000004556 brain Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 239000006172 buffering agent Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
- 235000019445 benzyl alcohol Nutrition 0.000 description 5
- 239000012217 radiopharmaceutical Substances 0.000 description 5
- 229940121896 radiopharmaceutical Drugs 0.000 description 5
- 230000002799 radiopharmaceutical effect Effects 0.000 description 5
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 5
- 235000019345 sodium thiosulphate Nutrition 0.000 description 5
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 4
- 125000004185 ester group Chemical group 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 229940037001 sodium edetate Drugs 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 235000011150 stannous chloride Nutrition 0.000 description 4
- 239000001119 stannous chloride Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 235000019800 disodium phosphate Nutrition 0.000 description 3
- 239000012216 imaging agent Substances 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 3
- RNMCCPMYXUKHAZ-UHFFFAOYSA-N 2-[3,3-diamino-1,2,2-tris(carboxymethyl)cyclohexyl]acetic acid Chemical compound NC1(N)CCCC(CC(O)=O)(CC(O)=O)C1(CC(O)=O)CC(O)=O RNMCCPMYXUKHAZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- LQPLDXQVILYOOL-UHFFFAOYSA-I pentasodium;2-[bis[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)CC([O-])=O LQPLDXQVILYOOL-UHFFFAOYSA-I 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229910052713 technetium Inorganic materials 0.000 description 2
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YXTDAZMTQFUZHK-ZVGUSBNCSA-L (2r,3r)-2,3-dihydroxybutanedioate;tin(2+) Chemical compound [Sn+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O YXTDAZMTQFUZHK-ZVGUSBNCSA-L 0.000 description 1
- TYYIOZHLPIBQCJ-UHFFFAOYSA-N 4-[1-(4-aminophenyl)-2,2,2-trichloroethyl]aniline Chemical class C1=CC(N)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(N)C=C1 TYYIOZHLPIBQCJ-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- VXAPDXVBDZRZKP-UHFFFAOYSA-N nitric acid phosphoric acid Chemical compound O[N+]([O-])=O.OP(O)(O)=O VXAPDXVBDZRZKP-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940007163 stannous tartrate Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
Definitions
- the present invention relates to a composition for producing a technetium-labeled radiopharmaceutical used for cerebral blood flow diagnosis using a brain function imaging method.
- the brain is an important organ that controls life, and operates by taking in oxygen from a normal amount of blood that is constantly sent to the brain.
- the blood flow to the brain is reduced or disrupted, which not only reduces the function of the brain but also necroses the brain cells. Therefore, a method for diagnosing cerebral blood flow has been devised.
- DAD T diaminedithiol
- ester group DADT compound penetrates the blood-brain barrier and is taken into the brain parenchyma, undergoes enzymatic degradation in the brain and is metabolized to polar compounds, so it loses the blood-brain barrier permeability, into the brain parenchyma It is thought to be retained.
- ester group of 99mT c_ECD was hydrolyzed in brain tissue and rapidly metabolized to a polar compound with no blood-brain barrier permeability, proportional to cerebral blood flow. It has been confirmed by Wa Io Vitch et al. That it accumulates in the brain parenchyma and is retained in the cell for a long time.
- the ester group of 99mT c_E CD has low affinity with blood cell components and soft tissues, and since it has a high clearance from organs and blood other than the brain, images with a low background can be obtained. Therefore, 99 mT c-ECD is useful as a radiopharmaceutical for cerebral blood flow diagnosis and is widely used.
- the 99mT c_ECD-containing drug currently on the market is an injection for preparation at the time of use consisting of two vials, vial A and vial B.
- Vial A contains N, N '_ (1,2-ethylene) bis-L-cystine jetyl ester (hereinafter referred to as EC D)' dihydrochloride, stannous chloride, sodium edetate, D_mannitol
- EC D (1,2-ethylene) bis-L-cystine jetyl ester
- stannous chloride sodium edetate
- the solution of the composition A containing lyophilized product is freeze-dried
- the vial B is a solution of the composition B consisting of sodium dihydrogen phosphate and sodium hydrogen phosphate.
- 99mT c— ECD was prepared by adding 3 mL or less of 99 m T c sodium pertechnetate to vial B, adding 1 mL from vial A to 3 mL of solution into vial B, stirring thoroughly, and Leave for 30 minutes.
- Patent Document 1 Japanese Patent Publication No. 7_64802
- the present invention provides a pharmaceutical assembly for efficiently labeling ECD with 99mTc in a short time.
- the purpose is to provide a composition.
- the present inventor conducted an 99mTc labeling reaction in the presence of an acidic substance or a salt thereof in addition to ECD and a reducing agent. As a result, the present inventors have found that a radiopharmaceutical for diagnosing local cerebral blood flow that can significantly reduce the reaction time and can cope with an emergency test has been completed.
- the present invention is characterized by containing N, N ′-(1,2_ethylene) bis-L-cystinejetyl ester or a salt thereof, a reducing agent and an acidic substance or a salt thereof.
- the present invention provides a composition for producing [N, N′-ethylenedi-L-cystineate (3 —)] oxotechnetium (99mT c) jetyl ester.
- N, N '-(1,2-ethylene) bis-L-cystine jetyl ester or a salt thereof is added to 99mTc pertechnetic acid or a salt thereof in the presence of a reducing agent and an acidic substance or a salt thereof.
- the present invention provides a method for producing [N, N'-ethylenedi-L-cystinate (3 _)] oxotechnetium (9 9mT c) jetyl ester characterized by reacting a salt.
- the present invention provides an injection solution containing [N, N′-ethylenedi_L_cystineate (3 _)] oxotechnetium (99mTc) jet ester obtained by the above production method.
- FIG. 5 is a graph showing the relationship between the elapsed time after labeling and the radiochemical purity of 99 m T c — ECD.
- the 99mT c_ECD production method of the present invention is carried out by reacting ECD or a salt thereof with 99mT c pertechnetic acid or a salt thereof in the presence of a reducing agent and an acidic substance or a salt thereof.
- the salt of ECD include acid addition salts of ECD, such as EC D hydrochloride, ECD sulfate, ECD nitrate, etc., but ECD hydrochloride, particularly EC D dihydrochloride is preferred. .
- Examples of the reducing agent include alkali metal nitrite, stannous salt, sodium borohydride and the like, but stannous salt is preferable, and further, stannous nitrate, stannous tartrate. Tin and stannous chloride are preferred, and stannous chloride is particularly preferred.
- the amount of reducing agent used depends on the amount of 99mTc pertechnetic acid or its salt, but it is 0.001 to 0.10 mg, or 0 to 0.1 mg of ECD or its salt. 0 1 to 0.05 kg, especially 0.024 mg is preferred.
- the present invention is characterized in that an acidic substance or a salt thereof is used. Although the reason why an acidic substance or a salt thereof significantly shortens the 99 mT c labeling reaction is not clear, it is considered to promote the reduction reaction of the labeling agent by the reducing agent.
- an acidic substance or a salt thereof include ascorbic acid or a salt thereof, citrate or a salt thereof, sulfite or a salt thereof, gentisic acid or a salt thereof, thiosulfate, pyrosulfite, and bisulfite. These may be used alone or in combination of two or more.
- alkali metal salts such as sodium salt and potassium salt are preferable.
- ascorbic acid or its sodium salt citrate or its sodium salt
- sodium sulfite gentisic acid or its sodium salt
- sodium thiosulfate sodium pyrosulfite
- sulfite Sodium hydride is preferred.
- the amount of these acidic substances or salts thereof used is preferably 1 to 60 Omg, more preferably 5 to 15 Omg with respect to 0.3 mg of ECD or a salt thereof.
- ascorbic acid or a salt thereof is preferably 10 to 60 Omg, particularly 50 to 20 Omg with respect to 0.3 mg of ECD or a salt thereof.
- Cuenic acid or a salt thereof is preferably “! To 10 Omg, especially 10 to 10 Omg relative to 0.3 mg of ECD or a salt thereof.
- Sulfurous acid or a salt thereof is preferably 0.3 mg of ECD or a salt thereof.
- 1 to 10 Omg, particularly 20 to 5 Omg is preferable
- Gentic acid or a salt thereof is preferably 1 to 20 mg, particularly 7.5 mg, relative to 0.3 mg of ECD or a salt thereof.
- the sulfate is preferably 1 to 10 Omg, particularly 5 to 2 Omg, with respect to 0.3 mg of ECD or a salt thereof
- Pyrosulfite is preferably 1 to 100 mg, particularly with respect to 0.3 mg of ECD or a salt thereof. 5-20 mg is preferred
- Bisulfite salt is "! against 0.3 mg of ECD or its salt! ⁇ 10 Omg, particularly 10 to 5 Omg is preferred.
- thiosulfate it is preferable to use benzyl alcohol together.
- the labeling agent 99mTc pertechnetic acid or a salt thereof, an alkaline metal salt such as 99mTc pertechnetate sodium is preferable.
- the amount of labeling agent used is preferably 37-7400 MBq, particularly 600 MBq at the time of labeling with respect to 0.3 mg of ECD or a salt thereof.
- This labeling agent is preferably prepared before the reaction by a conventional method, for example, sodium pertechnetate (99mTc) injection solution generator.
- the reaction is preferably carried out in a solution of pH 6-9, particularly in a buffer solution of pH 6-9, the reaction efficiency, the point of use as an injection solution after the reaction, the point of labeling purity It is preferable.
- the buffer solution of pH 6-9 may be in an aqueous solution containing a buffer capable of adjusting pH to 6-9, and examples thereof include a phosphate buffer, a citrate buffer, and a tartrate buffer.
- a pH 6-8 buffer, particularly a phosphate buffer is more preferable, and a mixture of sodium hydrogen phosphate and sodium hydrogen phosphate is particularly preferable. preferable.
- chelating agents such as sodium edetate, sodium diethylenetriaminepentaacetate, cyclohexanediaminetetraacetic acid; stabilizers such as D-mannitol, lactose and glucose; storage of benzyl alcohol and the like Agents, sodium chloride isotonic agents and the like may be present.
- the reaction is preferably carried out under the condition that the concentration of ECD or a salt thereof is 0.03 to 0.3 mgZmL, particularly 0.06 to 0.1 mgZmL. Ingredients other than ECD or its salts are preferably added according to this concentration and reacted.
- the reaction is preferably carried out at 4 to 70 ° C, particularly 10 to 30 ° C.
- the time required for the reaction is within 5 minutes, preferably within 1 minute, which is significantly shorter than the conventional method.
- the production of the labeling agent is usually performed before the reaction. Therefore, in the present invention, it is preferable to prepare in advance a composition containing ECD or a salt thereof, a reducing agent and an acidic substance or a salt thereof as a composition for producing 99mT c_ECD. Further, a buffering agent for adjusting the liquidity to pH 6 to 9 can also be contained in the composition in advance.
- At least ECD or a salt thereof and the buffering agent react if they are kept in contact with each other, so that they are stored in separate containers or are not in contact with each other. It is preferable to be stored in one container.
- the form of the composition for producing 99mT c_ECD of the present invention includes the following forms. (1) A combination of a composition A containing ECD or a salt thereof and a composition B containing a reducing agent, an acidic substance or a salt thereof and a buffer; (2) containing ECD or a salt thereof and a reducing agent Composition A; Combination of composition B containing acidic substance or salt thereof and buffer; (3) Composition A containing ECD or salt thereof, reducing agent, and acidic substance or salt thereof, and buffer And a combination with the composition B containing the agent.
- buffer When (2) is contained, the above (2) is particularly preferable.
- chelating agents such as sodium edetate, sodium diethylenetriaminepentaacetate, cyclohexanediaminetetraacetic acid; stabilizers such as D_mannitol, lactose, glucose; preservatives such as benzyl alcohol; A sodium chloride salt isotonic agent and the like can be combined.
- a form in which the buffering agent is removed from the above (1), (2) and (3) is preferable.
- a composition containing ECD or a salt thereof is dissolved in physiological saline or the like, and then a labeling agent is added. What is necessary is just to add an ingredient.
- the obtained 99mT c_ECD-containing liquid can be used as a radiopharmaceutical for local cerebral blood flow diagnosis as it is.
- 99mT c_ECD having a radiochemical purity of 95% or more can be obtained within 5 minutes or even within 1 minute of the labeling reaction. Further, since the reaction efficiency is high, the volume of the composition A can be reduced to 1Z2 to 1Z10 as compared with the conventional product.
- Neurolite TM Daiichi (Daiichi Radioisotope Laboratory).
- Neurolite TM 1 is an in-use preparation consisting of two vials, vial A and vial B.
- Viral A is a lyophilized composition containing ECD, dihydrochloride, stannous chloride, sodium edetate, D-mannitol, and vial B contains sodium dihydrogen phosphate and nitric acid hydrogen phosphate. It is a solution made of lime. The signs were used as follows.
- the radiochemical purity of 99mT c-E C D was analyzed by thin layer chromatography.
- the unbound 99mTc sodium pertechnetate solution contained in 99mTc-ECD developed an R f of 0.8 to 1.0. From the above, the radiochemical purity of 99mTc—ECD can be calculated by the following formula.
- 99mT c_ECD was prepared in accordance with Reference Example 1 after changing the contents of vial B, which is an existing composition for the first preparation of Neurorai h TM , to 1 mL of ascorbic acid solution prepared to pH 8.0.
- the elapsed time after labeling and radiochemical purity were confirmed by the method shown in Reference Example 2 and compared with the conventional method.
- the concentration of the ascorbic acid solution at this time was 1 O OmgZmL, and the radioactivity and liquid volume in this implementation were 600 MBq and 4 m, respectively.
- Figure 1 shows a comparison of labeling time and radiochemical purity between the existing method and the ascorbic acid method in which the contents of vial B were changed to a scorbic acid solution in the preparation of 99mT c_E CD.
- PH of ascorbic acid solution is 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, concentration of ascorbic acid solution (mgZmL) is 100, 1 50
- concentration of ascorbic acid solution is 100, 1 50
- the radiochemical purity after 0.5, 1, 3, 5, and 30 minutes after labeling was examined by the method shown in Reference Example 2 for the combination of pH and concentration. .
- the radioactivity and liquid volume at the time of labeling in this implementation were 600 MBq and 4 ml, respectively.
- ascorbic acid solution concentrations 50, 100, and 150.
- radiochemistry After 0.5, 1, 3, and 30 minutes after labeling The purity was examined by the method shown in Reference Example 2.
- the radioactivity and liquid volume at the time of labeling in this implementation were 600 MBq and 4 mL, respectively.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Optics & Photonics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008507373A JP5144497B2 (ja) | 2006-03-24 | 2007-03-23 | 局所脳血流診断用放射性医薬品製造用組成物 |
US12/294,067 US20090209740A1 (en) | 2006-03-24 | 2007-03-23 | Composition for preparation of radioactive pharmaceutical for diagnosis of regional cerebral blood flow |
EP07736940A EP2000154A4 (en) | 2006-03-24 | 2007-03-23 | COMPOSITION FOR PREPARING A RADIOACTIVE PHARMACEUTICAL FOR THE DIAGNOSIS OF REGIONAL CEREBRAL BLOOD FLOW |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006083664 | 2006-03-24 | ||
JP2006-083664 | 2006-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007111020A1 true WO2007111020A1 (ja) | 2007-10-04 |
Family
ID=38540955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/000283 WO2007111020A1 (ja) | 2006-03-24 | 2007-03-23 | 局所脳血流診断用放射性医薬品製造用組成物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20090209740A1 (ja) |
EP (1) | EP2000154A4 (ja) |
JP (1) | JP5144497B2 (ja) |
WO (1) | WO2007111020A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63295549A (ja) * | 1987-02-18 | 1988-12-01 | ザ・デュポン・メルク・ファーマシュウティカル・カンパニー | エステル置換ジアミンジチオール類およびそれらの放射線標識錯化合物 |
JPH0797361A (ja) * | 1993-06-30 | 1995-04-11 | Nippon Mejifuijitsukusu Kk | 新規なキレート形成性化合物とその用途 |
JPH07173132A (ja) * | 1993-10-25 | 1995-07-11 | Nippon Mejifuijitsukusu Kk | キレート形成性フェニルジアミノジチオール誘導体及 びその用途 |
JP2002205959A (ja) * | 2001-01-10 | 2002-07-23 | Photochemical Co | 骨髄シンチグラフィ用薬剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4042676A (en) * | 1975-10-09 | 1977-08-16 | Union Carbide Corporation | Technetium-99m labeled radiodiagnostic agents for liver and bone marrow scanning and method of preparation |
US4452774A (en) * | 1982-04-30 | 1984-06-05 | President And Fellows Of Harvard College | Isonitrile radionuclide complexes for labelling and imaging agents |
FR2655339B2 (fr) * | 1989-04-19 | 1992-04-10 | Medgenix Group Sa | Composes et complexes utiles notamment en imagerie medicale. |
US5688485A (en) * | 1992-12-31 | 1997-11-18 | The Dupont Merck Pharmaceutical Company | Radiolabelled complexes of ester-substituted diaminethiols |
CN1072020C (zh) * | 1996-04-11 | 2001-10-03 | 北京耐思达新技术发展公司 | 99m锝(Tc)标记用脑灌注显像剂双半胱乙酯药盒的一步法制备 |
JPH1059990A (ja) * | 1996-08-14 | 1998-03-03 | Daiichi Rajio Isotope Kenkyusho:Kk | 放射性標識ウリジン誘導体およびこれを含む医薬 |
US6403054B1 (en) * | 1997-05-28 | 2002-06-11 | Bristol-Myers Squibb Pharma Company | Ternary ligand complexes useful as radiopharmaceuticals |
-
2007
- 2007-03-23 WO PCT/JP2007/000283 patent/WO2007111020A1/ja active Application Filing
- 2007-03-23 EP EP07736940A patent/EP2000154A4/en not_active Withdrawn
- 2007-03-23 US US12/294,067 patent/US20090209740A1/en not_active Abandoned
- 2007-03-23 JP JP2008507373A patent/JP5144497B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63295549A (ja) * | 1987-02-18 | 1988-12-01 | ザ・デュポン・メルク・ファーマシュウティカル・カンパニー | エステル置換ジアミンジチオール類およびそれらの放射線標識錯化合物 |
JPH0764802B2 (ja) | 1987-02-18 | 1995-07-12 | ザ・デュポン・メルク・ファーマシュウティカル・カンパニー | エステル置換ジアミンジチオール類およびそれらの放射線標識錯化合物 |
JPH0797361A (ja) * | 1993-06-30 | 1995-04-11 | Nippon Mejifuijitsukusu Kk | 新規なキレート形成性化合物とその用途 |
JPH07173132A (ja) * | 1993-10-25 | 1995-07-11 | Nippon Mejifuijitsukusu Kk | キレート形成性フェニルジアミノジチオール誘導体及 びその用途 |
JP2002205959A (ja) * | 2001-01-10 | 2002-07-23 | Photochemical Co | 骨髄シンチグラフィ用薬剤 |
Non-Patent Citations (2)
Title |
---|
"Saikin no Shinyaku (Dai 46 Shu) - 1995 Nenpan-", KABUSHIKI KAISHA YAKUJI NIPPOSHA, 3 April 1995 (1995-04-03), pages 302, XP003018155 * |
See also references of EP2000154A4 * |
Also Published As
Publication number | Publication date |
---|---|
US20090209740A1 (en) | 2009-08-20 |
JPWO2007111020A1 (ja) | 2009-08-06 |
JP5144497B2 (ja) | 2013-02-13 |
EP2000154A9 (en) | 2009-03-18 |
EP2000154A2 (en) | 2008-12-10 |
EP2000154A4 (en) | 2010-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pandya et al. | Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development | |
JP2530112B2 (ja) | 腎機能測定用の放射能標識テクネチウムキレ―トを含むキット | |
IE58395B1 (en) | Nmr contrast agents | |
WO2019027059A1 (ja) | 放射標識されたアリール化合物の製造方法 | |
JPH05306221A (ja) | 腸管洗浄液用組成物及び腸管洗浄液 | |
US5245018A (en) | Process for preparing a radiopharmaceutical composition | |
Hernández-Gil et al. | Development of 68 Ga-labelled ultrasound microbubbles for whole-body PET imaging | |
Burianova et al. | Radiotracers for positron emission tomography (PET) targeting tumour-associated carbonic anhydrase isoforms | |
KR850001871B1 (ko) | 비-방사성 담체조성물 및 이를 사용한 방사성 진단제의 제조방법 | |
US4208398A (en) | Technetium-labeled complexes, production and use thereof | |
Li et al. | Advances in macrocyclic chelators for positron emission tomography imaging | |
US11384106B2 (en) | Metal tricarbonyl complexes comprising substituted iminodiactic acid ligands and uses as radioisotope tracers | |
WO2007111020A1 (ja) | 局所脳血流診断用放射性医薬品製造用組成物 | |
ES2223559T3 (es) | Complejos de metales de transicion del grupo (vii) con ligandos aminopolicarboxilato multidentados y kit para producirlos. | |
US4031198A (en) | Technetium-labeled complexes, production and use thereof | |
Lima et al. | TETA analogue containing one methylenephosphonate pendant arm: Lanthanide complexes and biological evaluation of its 153Sm and 166Ho complexes | |
KR20190094192A (ko) | 영상화제 및 그의 사용 | |
Pasha et al. | Synthesis and evaluation of lanthanide ion DOTA–tetraamide complexes bearing peripheral hydroxyl groups | |
JP5105343B2 (ja) | 局所脳血流診断用放射性医薬品 | |
JP4276377B2 (ja) | 安定な放射性医薬品 | |
JPH0625015A (ja) | 放射性医薬品調製用キャリヤー | |
US4617184A (en) | 99m Tc-1,2-dihydroxy-1,2-bis(dihydroxyphosphinyl)ethane complex for skeleton scanning | |
AllenáChang | Selectivity of macrocyclic aminocarboxylates for alkaline-earth metal ions and stability of their complexes | |
KR102548998B1 (ko) | 혈전영상을 위한 방사성의약품 및 조성물 | |
WO2023100852A1 (ja) | 安定化放射性医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07736940 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2008507373 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007736940 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12294067 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |